Humacyte (HUMA) News Today $2.88 -0.44 (-13.25%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$2.33 -0.56 (-19.27%) As of 03/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Humacyte 25M share Spot Secondary priced at $2.00March 26 at 4:26 AM | markets.businessinsider.comHumacyte stock slides on pricing public offering of units to raise $50MMarch 26 at 4:26 AM | msn.comHumacyte (HUMA) Projected to Post Earnings on FridayHumacyte (NASDAQ:HUMA) will be releasing earnings before the market opens on Friday, March 28, Financial Modeling Prep reports.March 26 at 1:45 AM | marketbeat.comHumacyte, Inc. Announces Pricing of Public Offering of Common StockMarch 25 at 8:35 PM | globenewswire.comUS Approved Device for Battlefield Injuries Despite Serious Risks, Former FDA Reviewer SaysMarch 25 at 6:25 PM | msn.comHumacyte down 13% amid reports that FDA approved device despite warningsMarch 25 at 6:25 PM | msn.comHumacyte's Stock Drops Below 52-Week Low Amidst Share SaleMarch 25 at 6:25 PM | marketwatch.comHumacyte, Inc. Announces Proposed Public Offering of Common StockMarch 25 at 4:01 PM | globenewswire.comF.D.A. Approved Lab-Grown Blood Vessel DespiteWarningsMarch 24 at 5:05 PM | nytimes.comHumacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade)March 24 at 12:04 PM | seekingalpha.comHumacyte (HUMA) to Release Earnings on FridayHumacyte (NASDAQ:HUMA) will be releasing earnings before the market opens on Friday, March 28, Financial Modeling Prep reports.March 21, 2025 | marketbeat.comHumacyte's (HUMA) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Humacyte in a research report on Wednesday.March 13, 2025 | marketbeat.comHumacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's WhyMarch 12, 2025 | msn.comHumacyte announces publication of Budget Impact Model for SymvessMarch 10, 2025 | markets.businessinsider.comHumacyte price target lowered to $7.50 from $10 at TD CowenMarch 10, 2025 | markets.businessinsider.comHumacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical EconomicsMarch 10, 2025 | globenewswire.comTrestle Bio Unveils Research Partnership With HumacyteMarch 8, 2025 | nasdaq.comD. Boral Capital Reiterates "Buy" Rating for Humacyte (NASDAQ:HUMA)D. Boral Capital restated a "buy" rating and issued a $25.00 target price on shares of Humacyte in a report on Friday.March 8, 2025 | marketbeat.comTrestle Bio Announces Research Collaboration with HumacyteMarch 6, 2025 | finance.yahoo.comHumacyte, Trestle Biotherapeutics announce research collaborationMarch 6, 2025 | markets.businessinsider.comHumacyte, Inc. (NASDAQ:HUMA) Receives Consensus Rating of "Buy" from BrokeragesHumacyte, Inc. (NASDAQ:HUMA - Get Free Report) has received an average recommendation of "Buy" from the eight research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a stronMarch 4, 2025 | marketbeat.comHumacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025March 3, 2025 | globenewswire.comHumacyte's (HUMA) "Buy" Rating Reiterated at BenchmarkBenchmark reaffirmed a "buy" rating on shares of Humacyte in a research report on Thursday.February 28, 2025 | marketbeat.comHumacyte to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 27, 2025 | globenewswire.comHumacyte shares rise after patent for bioengineered human tissues manufacturingFebruary 27, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Andlauer Healthcare Group (OtherANDHF) and Humacyte (HUMA)February 27, 2025 | markets.businessinsider.comHumacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered TissuesFebruary 27, 2025 | globenewswire.comHumacyte announces commercial launch of SymvessFebruary 26, 2025 | markets.businessinsider.comHumacyte (NASDAQ:HUMA) Given "Buy" Rating at D. Boral CapitalD. Boral Capital reiterated a "buy" rating and issued a $25.00 price target on shares of Humacyte in a report on Wednesday.February 26, 2025 | marketbeat.comHumacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular TraumaFebruary 26, 2025 | globenewswire.comHumacyte, Inc. (NASDAQ:HUMA) Stock Holdings Boosted by Private Advisor Group LLCPrivate Advisor Group LLC grew its holdings in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 60.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 599,700 shares of the company's stock afFebruary 25, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Short Interest UpdateHumacyte, Inc. (NASDAQ:HUMA - Get Free Report) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 24,040,000 shares, a decrease of 6.2% from the January 15th total of 25,640,000 shares. Approximately 23.0% of the company's shares are sold short. Based on an average daily trading volume, of 4,330,000 shares, the short-interest ratio is presently 5.6 days.February 18, 2025 | marketbeat.comNorth Carolina biotech weighs demand as breakthrough treatment hits marketFebruary 12, 2025 | bizjournals.comLJI Wealth Management LLC Takes Position in Humacyte, Inc. (NASDAQ:HUMA)LJI Wealth Management LLC acquired a new stake in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 185,000 shares of the company's stock, valued atFebruary 9, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Given Consensus Rating of "Buy" by BrokeragesShares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have earned a consensus rating of "Buy" from the eight research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, six have assigned a buy ratingFebruary 7, 2025 | marketbeat.com83,500 Shares in Humacyte, Inc. (NASDAQ:HUMA) Acquired by Trilogy Capital Inc.Trilogy Capital Inc. acquired a new stake in Humacyte, Inc. (NASDAQ:HUMA - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 83,500 shares of the company's stock, valued at approximately $422,000. Trilogy Capital Inc.February 7, 2025 | marketbeat.comHumacyte and Pluristyx enhance partnership for diabetes treatmentJanuary 28, 2025 | msn.comHumacyte, Pluristyx announce expanded partnershipJanuary 28, 2025 | markets.businessinsider.comHumacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCsJanuary 28, 2025 | markets.businessinsider.comWealth Effects LLC Boosts Stake in Humacyte, Inc. (NASDAQ:HUMA)Wealth Effects LLC boosted its position in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 89.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 121,400 shares of the company's stock after acquiring an additional 57,200 sharesJanuary 28, 2025 | marketbeat.comHumacyte: Upside Potential, But I Will Wait For Revenue TrendsJanuary 25, 2025 | seekingalpha.comHUMACYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating Humacyte, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJanuary 23, 2025 | globenewswire.comBrokers Set Expectations for Humacyte FY2025 EarningsHumacyte, Inc. (NASDAQ:HUMA - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Humacyte in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the company will poJanuary 23, 2025 | marketbeat.comHumacyte announces planned IND filing in 2025 for sdATEV for CABGJanuary 22, 2025 | markets.businessinsider.comHumacyte moves to test bioengineered vessel in heart surgeryJanuary 22, 2025 | msn.comHumacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral CapitalD. Boral Capital reissued a "buy" rating and issued a $25.00 target price on shares of Humacyte in a report on Tuesday.January 21, 2025 | marketbeat.comHumacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass GraftingJanuary 21, 2025 | globenewswire.comCantor Fitzgerald Increases Earnings Estimates for HumacyteHumacyte, Inc. (NASDAQ:HUMA - Free Report) - Investment analysts at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for Humacyte in a research note issued to investors on Wednesday, January 15th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($1January 18, 2025 | marketbeat.comHumacyte (NASDAQ:HUMA) Stock Price Up 10% - Time to Buy?Humacyte (NASDAQ:HUMA) Trading 10% Higher - Should You Buy?January 17, 2025 | marketbeat.comHUMA DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMAJanuary 17, 2025 | globenewswire.com Remove Ads Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address HUMA Media Mentions By Week HUMA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HUMA News Sentiment▼0.710.77▲Average Medical News Sentiment HUMA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HUMA Articles This Week▼99▲HUMA Articles Average Week Remove Ads Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SDGR News Today AAPG News Today IDYA News Today WVE News Today IMCR News Today ANIP News Today DYN News Today INDV News Today AMPH News Today ETNB News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HUMA) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
